These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 10990198

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells.
    Schneider A, Schmalix WA, Siruguri V, de Groene EM, Horbach GJ, Kleingeist B, Lang D, Böcker R, Belloc C, Beaune P, Greim H, Doehmer J.
    Arch Biochem Biophys; 1996 Aug 15; 332(2):295-304. PubMed ID: 8806738
    [Abstract] [Full Text] [Related]

  • 45. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG.
    J Pharmacol Exp Ther; 2002 Oct 15; 303(1):323-32. PubMed ID: 12235267
    [Abstract] [Full Text] [Related]

  • 46. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
    Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH.
    J Pharmacol Exp Ther; 2001 Jul 15; 298(1):323-30. PubMed ID: 11408558
    [Abstract] [Full Text] [Related]

  • 47. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
    Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS, van den Anker JN, Leeder JS.
    Clin Pharmacol Ther; 2003 Mar 15; 73(3):209-22. PubMed ID: 12621386
    [Abstract] [Full Text] [Related]

  • 48. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec 15; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
    Satoh T, Fujita KI, Munakata H, Itoh S, Nakamura K, Kamataki T, Itoh S, Yoshizawa I.
    Anal Biochem; 2000 Nov 15; 286(2):179-86. PubMed ID: 11067738
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 54. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
    Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB.
    Mol Pharmacol; 1997 May 15; 51(5):741-54. PubMed ID: 9145912
    [Abstract] [Full Text] [Related]

  • 55. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Pharm Res; 2000 Oct 15; 17(10):1189-97. PubMed ID: 11145223
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.
    Pfrunder A, Gutmann H, Beglinger C, Drewe J.
    J Pharm Pharmacol; 2003 Jan 15; 55(1):59-66. PubMed ID: 12625868
    [Abstract] [Full Text] [Related]

  • 58. Vitamin D Receptor-Mediated Upregulation of CYP3A4 and MDR1 by Quercetin in Caco-2 cells.
    Chae YJ, Cho KH, Yoon IS, Noh CK, Lee HJ, Park Y, Ji E, Seo MD, Maeng HJ.
    Planta Med; 2016 Jan 15; 82(1-2):121-30. PubMed ID: 26366751
    [Abstract] [Full Text] [Related]

  • 59. Involvement of CYP3A4 and MDR1 in altered metabolism and transport of indinavir in 1,25(OH)2D3-treated Caco-2 cells.
    Lee SJ, Joo SA, Kim H, Lee Y, Chung SJ, Chae YJ, Maeng HJ.
    Eur J Pharm Sci; 2023 Apr 01; 183():106396. PubMed ID: 36736464
    [Abstract] [Full Text] [Related]

  • 60. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
    Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, Sakaeda T, Okumura K, Langguth P, Yamashita S.
    Drug Metab Pharmacokinet; 2006 Oct 01; 21(5):414-23. PubMed ID: 17072095
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.